Literature DB >> 20563895

Metastatic colorectal cancer with severe liver dysfunction successfully treated using FOLFOX therapy.

Takaya Shimura, Hiromi Kataoka, Yoshikazu Hirata, Takashi Mizushima, Kenji Murakami, Motoshi Mabuchi, Tsutomu Mizoshita, Eiji Kubota, Satoshi Tanida, Takeshi Kamiya, Takashi Joh.   

Abstract

INTRODUCTION: The liver is the most frequent site of metastases from colorectal cancer (CRC), and extensive liver metastases often cause severe secondary liver dysfunction. However, whether chemotherapy for metastatic CRC with severe liver dysfunction offers any clinical benefit is unclear since patients in this setting are typically excluded from clinical trials. DISCUSSION: We report herein a case of metastatic sigmoid colon cancer with severe liver dysfunction that was successfully treated using infusional 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX). FOLFOX was effective and well tolerated in the present case, and subsequent addition of bevacizumab to FOLFOX after disease progression was similarly feasible.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20563895     DOI: 10.1007/s12029-010-9176-6

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  16 in total

1.  Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study.

Authors:  Charles S Fuchs; John Marshall; José Barrueco
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

2.  Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients.

Authors:  C H Köhne; D Cunningham; F Di Costanzo; B Glimelius; G Blijham; E Aranda; W Scheithauer; P Rougier; M Palmer; J Wils; B Baron; F Pignatti; P Schöffski; S Micheel; H Hecker
Journal:  Ann Oncol       Date:  2002-02       Impact factor: 32.976

3.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

Review 4.  Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

Authors:  R H Mathijssen; R J van Alphen; J Verweij; W J Loos; K Nooter; G Stoter; A Sparreboom
Journal:  Clin Cancer Res       Date:  2001-08       Impact factor: 12.531

5.  5-fluorouracil leucovorin and oxaliplatin (FOLFOX) in the treatment of metastatic colon cancer with severe liver dysfunction.

Authors:  Marwan G Fakih
Journal:  Oncology       Date:  2004       Impact factor: 2.935

6.  Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study.

Authors:  Timothy W Synold; Chris H Takimoto; James H Doroshow; David Gandara; Sridhar Mani; Scot C Remick; Daniel L Mulkerin; Anne Hamilton; Sunil Sharma; Ramesh K Ramanathan; Heinz Josef Lenz; Martin Graham; Jeffrey Longmate; Bennett M Kaufman; Percy Ivy
Journal:  Clin Cancer Res       Date:  2007-06-15       Impact factor: 12.531

7.  FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.

Authors:  Christophe Tournigand; Thierry André; Emmanuel Achille; Gérard Lledo; Michel Flesh; Dominique Mery-Mignard; Emmanuel Quinaux; Corinne Couteau; Marc Buyse; Gérard Ganem; Bruno Landi; Philippe Colin; Christophe Louvet; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2003-12-02       Impact factor: 44.544

8.  Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors:  Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

9.  A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.

Authors:  A P Venook; C Enders Klein; G Fleming; D Hollis; C G Leichman; R Hohl; J Byrd; D Budman; M Villalona; J Marshall; G L Rosner; J Ramirez; H Kastrissios; M J Ratain
Journal:  Ann Oncol       Date:  2003-12       Impact factor: 32.976

10.  Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.

Authors:  Howard S Hochster; Lowell L Hart; Ramesh K Ramanathan; Barrett H Childs; John D Hainsworth; Allen L Cohn; Lucas Wong; Louis Fehrenbacher; Yousif Abubakr; M Wasif Saif; Lee Schwartzberg; Eric Hedrick
Journal:  J Clin Oncol       Date:  2008-07-20       Impact factor: 44.544

View more
  4 in total

Review 1.  Chemotherapy in patients with hepatobiliary cancers and abnormal hepatic function.

Authors:  Jun Gong; May Cho; Marwan Fakih
Journal:  J Gastrointest Oncol       Date:  2017-04

2.  Impact of granulocyte colony-stimulating factor on FOLFIRINOX-induced neutropenia prevention: A population pharmacokinetic/pharmacodynamic approach.

Authors:  Pauline Macaire; Justine Paris; Julie Vincent; François Ghiringhelli; Leïla Bengrine-Lefevre; Antonin Schmitt
Journal:  Br J Clin Pharmacol       Date:  2020-06-05       Impact factor: 4.335

3.  Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer.

Authors:  Pashtoon Murtaza Kasi; Gita Thanarajasingam; Heidi D Finnes; Jose C Villasboas Bisneto; Joleen M Hubbard; Axel Grothey
Journal:  Case Rep Oncol Med       Date:  2015-05-21

4.  FOLFIRI combined with bevacizumab as first-line treatment for metastatic colorectal cancer patients with hyperbilirubinemia after UGT1A1 genotyping.

Authors:  Yung-Sung Yeh; Meng-Lin Huang; Se-Fen Chang; Chin-Fan Chen; Huang-Ming Hu; Jaw-Yuan Wang
Journal:  Med Princ Pract       Date:  2014-03-08       Impact factor: 1.927

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.